Literature DB >> 27018992

Electrocardiographic Parameters Indicating Worse Evolution in Patients with Acquired Long QT Syndrome and Torsades de Pointes.

Piotr Kukla1, Marek Jastrzębski2, Kamil Fijorek3, Sebastian Stec4, Leszek Bryniarski2, Danuta Czarnecka2, Adrian Baranchuk5.   

Abstract

BACKGROUND: Acquired long QT syndrome (a-LQTS) is associated with life-threatening ventricular arrhythmias, mainly torsades de pointes (TdP). ECG parameters predicting evolving into ventricular fibrillation (VF) are ill defined. AIMS: To determine ECG parameters preceding and during TdP associated with higher risk of developing VF.
METHODS: We analyzed 151 episodes of TdP, recorded in 28 patients with a-LQTS (mean QTc 638 ms ± 57).
RESULTS: All 28 patients had prolonged QT interval, (mean QTc 638 ms ± 57) ranging from 502 ms to 858 ms correcting by Bazett's formula. The mean TdP heart rate was 218 bpm ± 38 (mean cycle length of TdP 274 ± 47 ms). We classified TdPs episodes into "slower"-TdP (s-TdP) < 220 bpm (range from 145-220 bpm) observed in 81 (53.6%) episodes and "faster"-TdP (f-TdP) ≥ 220 bpm (ranged from 221-281 bpm) observed in 70 (46.4%) episodes. Among 151 episodes of TdP, 21 (13.9%) were unstable (converted into VF). Out of 81 episodes of "slower"-TdP only 2 (2.5%) episodes converted into VF. The mean coupling interval (CI) of the PVC initiating TdP was 510 ms ± 118, the pause-RR interval was 1147 ms ± 335, the prematurity index (PI) of PVC that initiated TdP was 0.45 ± 0.13. The mean cycle length variability of TdP (VRV-TdP) was 30.79 ms ± 19.7. U wave was observed in 86 episodes (56.9%), among that in 69 episodes, the U/T wave ratio was > 1. Macro T wave alternans was observed in 4 patients. The QT interval was not different in patients with VF(+) and VF(-) episodes, 633 ± 60 and 639 ± 57, respectively.
CONCLUSIONS: Some electrocardiographic parameters can be helpful in determining the risk of TdP evolving into VF. The slower ventricular rate (< 220 bpm), the higher rate instability (VRV > 30 ms) and the short episodes < 20 beats could predict benign evolution.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  acquired long QT syndrome; torsades de pointes; ventricular fibrillation; ventricular rate variability

Mesh:

Year:  2016        PMID: 27018992      PMCID: PMC6931568          DOI: 10.1111/anec.12355

Source DB:  PubMed          Journal:  Ann Noninvasive Electrocardiol        ISSN: 1082-720X            Impact factor:   1.468


  11 in total

Review 1.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.

Authors:  D M Roden; R Lazzara; M Rosen; P J Schwartz; J Towbin; G M Vincent
Journal:  Circulation       Date:  1996-10-15       Impact factor: 29.690

2.  Mode of onset of torsade de pointes in congenital long QT syndrome.

Authors:  S Viskin; S R Alla; H V Barron; K Heller; L Saxon; I Kitzis; G F Hare; M J Wong; M D Lesh; M M Scheinman
Journal:  J Am Coll Cardiol       Date:  1996-11-01       Impact factor: 24.094

3.  Electrocardiographic Parameters Indicating Worse Evolution in Patients with Acquired Long QT Syndrome and Torsades de Pointes.

Authors:  Piotr Kukla; Marek Jastrzębski; Kamil Fijorek; Sebastian Stec; Leszek Bryniarski; Danuta Czarnecka; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-28       Impact factor: 1.468

4.  Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.

Authors:  Giselle Sarganas; Edeltraut Garbe; Andreas Klimpel; Rolf C Hering; Elisabeth Bronder; Wilhelm Haverkamp
Journal:  Europace       Date:  2013-07-05       Impact factor: 5.214

Review 5.  Long QT syndromes and torsade de pointes.

Authors:  S Viskin
Journal:  Lancet       Date:  1999-11-06       Impact factor: 79.321

6.  Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome.

Authors:  Takashi Noda; Wataru Shimizu; Kazuhiro Satomi; Kazuhiro Suyama; Takashi Kurita; Naohiko Aihara; Shiro Kamakura
Journal:  Eur Heart J       Date:  2004-12       Impact factor: 29.983

7.  Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.

Authors:  Paulus Kirchhof; Michael R Franz; Abdennasser Bardai; Arthur M Wilde
Journal:  J Am Coll Cardiol       Date:  2009-07-07       Impact factor: 24.094

8.  Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias.

Authors:  A Leenhardt; E Glaser; M Burguera; M Nürnberg; P Maison-Blanche; P Coumel
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

9.  Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings.

Authors:  E H Locati; P Maison-Blanche; P Dejode; B Cauchemez; P Coumel
Journal:  J Am Coll Cardiol       Date:  1995-06       Impact factor: 24.094

Review 10.  Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia.

Authors:  S H Hohnloser; T Klingenheben; B N Singh
Journal:  Ann Intern Med       Date:  1994-10-01       Impact factor: 25.391

View more
  2 in total

1.  Electrocardiographic Parameters Indicating Worse Evolution in Patients with Acquired Long QT Syndrome and Torsades de Pointes.

Authors:  Piotr Kukla; Marek Jastrzębski; Kamil Fijorek; Sebastian Stec; Leszek Bryniarski; Danuta Czarnecka; Adrian Baranchuk
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-28       Impact factor: 1.468

2.  Predisposition of functional genetic variants of A-kinase anchoring protein 10 toward acquired repolarization disorders in high-risk vascular surgery patients.

Authors:  Jowita Biernawska; Joanna Solek-Pastuszka; Arkadiusz Kazimierczak; Krzysztof Safranow; Mariusz Kaczmarczyk; Malgorzata Zegan-Baranska; Maciej Zukowski; Katarzyna Kotfis
Journal:  Ther Clin Risk Manag       Date:  2018-07-26       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.